In World journal of gastroenterology ; h5-index 103.0
Colorectal cancer (CRC) is one of the most common malignancies of the digestive tract, with the annual incidence and mortality increasing consistently. Oxaliplatin-based chemotherapy is a preferred therapeutic regimen for patients with advanced CRC. However, most patients will inevitably develop resistance to oxaliplatin. Many studies have reported that non-coding RNAs (ncRNAs), such as microRNAs, long non-coding RNAs, and circular RNAs, are extensively involved in cancer progression. Moreover, emerging evidence has revealed that ncRNAs mediate chemoresistance to oxaliplatin by transcriptional and post-transcriptional regulation, and by epigenetic modification. In this review, we summarize the mechanisms by which ncRNAs regulate the initiation and development of CRC chemoresistance to oxaliplatin. Furthermore, we investigate the clinical application of ncRNAs as promising biomarkers for liquid CRC biopsy. This review provides new insights into overcoming oxaliplatin resistance in CRC by targeting ncRNAs.
Luo Zheng-Dong, Wang Yi-Feng, Zhao Yu-Xiao, Yu Long-Chen, Li Tian, Fan Ying-Jing, Zeng Shun-Jie, Zhang Yan-Li, Zhang Yi, Zhang Xin
2023-Jan-07
Colorectal cancer, Liquid biopsy biomarkers, Non-coding RNAs, Oxaliplatin, Resistance
